Journal
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Volume 32, Issue 8, Pages 509-517Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/jop.2015.0158
Keywords
purinergic; P2X; retina; rod pathway; retinal degeneration
Categories
Funding
- National Health and Medical Research Council of Australia [APP1027624, APP1061419]
- Macular Disease Foundation of Australia
Ask authors/readers for more resources
Purines, when present in the extracellular space, can mediate fast neurotransmission in the retina and central nervous system. Over the last decade there has been emerging evidence for the expression of P2X and P2Y receptors in a range of retinal neuronal subtypes. These results have highlighted important roles for purines in modulating specific retinal circuits, including the rod pathway and amacrine cell circuits. Traditionally, synaptic release of adenosine triphosphate (ATP) involves the novel anion vesicular nucleotide transporter, VNUT, which has recently been identified in a single wide-field amacrine cell population. In addition, nontraditional, conductive mechanisms of release have also been described in the retina. In the synapse, the enzymes involved in rapid degradation of purines are present in both plexiform layers of the retina. A role for P2X receptors in retinal diseases has also emerged recently. High concentrations of ATP lead to photoreceptor loss, through mechanisms involving P2X(7) receptors. In addition, activation of P2X(7) receptors is associated with activation of the inflammasome, a protein complex important for the release of proinflammatory cytokines. P2X receptors, especially P2X(7), are emerging as targets to combat retinal disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available